RKDA — Arcadia Biosciences, Inc. Dilution Risk Tracker

Arcadia Biosciences, Inc. (RKDA) carries a DilutionScore of 89/100, placing it in the Critical dilution risk tier — the highest category tracked by DilutionWatch. Companies at this level typically have active capital-raising programs, compressed cash runway, or a combination of dilution vectors that together represent meaningful downside risk to share count. As of July 14, 2026, this score reflects real-time data pulled directly from SEC EDGAR filings.

RKDA has an active ATM (at-the-market) program with $3.9M remaining capacity. ATM programs allow companies to sell shares continuously into the open market through a broker-dealer — without announcing a secondary offering. This creates a silent but steady source of share dilution that shows up in quarterly share count increases rather than a discrete offering event. DilutionWatch tracks 982,080 outstanding warrants for RKDA. Warrants become dilutive when exercised — converting to common shares at the strike price. Warrants near or in-the-money deserve particular attention since exercise can add materially to the outstanding share count within a short window.

DilutionWatch tracks over 25 SEC filing types for RKDA in real-time, scanning EDGAR every 60 seconds. A recent S-3 or registration statement filing appears in RKDA's filing history — this warrants monitoring for subsequent prospectus supplements (Form 424B), which indicate active capital raising. The DilutionWatch screener shows real-time score changes for RKDA alongside comparable critical-risk stocks. Not financial advice — this analysis is for informational purposes only.